Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.

The oncologist - 1 Aug 2016

Moore Kathleen N, Monk Bradley J

Abstract excerpt

UNLABELLED: : Our primary objective is to review the safety and tolerability profile of olaparib, a novel anticancer therapy, and to discuss key considerations for symptom management in patients with advanced ovarian cancer. Olaparib is the first of a new class of anticancer therapies, poly (ADP-ribose) polymerase (PARP) inhibitors that target tumors that have deficits in homologous recombination repair (such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Counseling
Share to Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Quality of Life

Source

Open in PubMed Open full text

Identifiers

PMID: 27256873
DOI: 10.1634/theoncologist.2015-0268
PMCID: PMC4978548

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.PMID 27256873Read ↗

Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.Semantic proximity Read ↗

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity Read ↗

Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian CancerSemantic proximity Read ↗

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.Semantic proximity Read ↗

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Semantic proximity Read ↗

Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.Semantic proximity Read ↗

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity Read ↗

Olaparib in the management of ovarian cancerSemantic proximity Read ↗

Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial.Semantic proximity Read ↗

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.Semantic proximity Read ↗

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Semantic proximity Read ↗

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.